Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1975 Apr 5;2(5961):17–19. doi: 10.1136/bmj.2.5961.17

Origin of urinary fibrin/fibrinogen degradation products in glomerulonephritis.

M Ekberg, M Pandolfi
PMCID: PMC1672971  PMID: 48398

Abstract

To elucidate the origin of the fibrin/fibrinogen degradation products (F.D.P.) occurring in the urine in glomerulonephritis 28 patients with glomerulonephritis were examined for renal fibrinolytic activity, F.D.P. in urine and serum, and blood fibrinolytic activators and blood fibrinolytic activators and inhibitors. Unlike the glomerful of healthy kidneys, which were fibrinolyticly inactive, those of kidneys with glomerulonephritis constantly showed fibrinolytic activity. The presence or absence of fibrin in the glomeruli was almost always accompanied by, respectively, the presence or absence of urinary F.D.P., which suggested a renal origin of urinary F.D.P. in glomerulonephritis. The low fibrinolytic activity of the blood and the absence of F.D.P. in the serum of these patients make it unlikely that the urinary F.D.P. in glomerulonephritis result from glomerular filtration.

Full text

PDF
17

Images in this article

18p18-a
on p.18

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergstein J. M., Michael A. F., Jr Cortical fibrinolytic activity in normal and diseased human kidneys. J Lab Clin Med. 1972 May;79(5):701–709. [PubMed] [Google Scholar]
  2. Franklin W. A., Simon N. M., Potter E. W., Krumlovsky F. A. The hemolytic-uremic syndrome. Arch Pathol. 1972 Sep;94(3):230–240. [PubMed] [Google Scholar]
  3. Ganrot P. O. Determination of alpha-2-macroglobulin as trypsin-protein esterase. Clin Chim Acta. 1966 Oct;14(4):493–501. doi: 10.1016/0009-8981(66)90037-4. [DOI] [PubMed] [Google Scholar]
  4. Hedner U., Ekberg M., Nilsson I. M. Urinary fibrin-fibrinogen degradation products (FDP) and glomerulonephritis. Acta Med Scand. 1974 Jan-Feb;195(1-2):81–85. [PubMed] [Google Scholar]
  5. Humair L., Potter E. V., Kwaan H. C. The role of fibrinogen in renal disease. I. Production of experimental lesions in mice. J Lab Clin Med. 1969 Jul;74(1):60–71. [PubMed] [Google Scholar]
  6. KWAAN H. C., ASTRUP T. LOCALIZATION OF FIBRINOLYTIC ACTIVITY IN THE EYE. Arch Pathol. 1963 Dec;76:595–601. [PubMed] [Google Scholar]
  7. Laurell C. B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966 Apr;15(1):45–52. doi: 10.1016/0003-2697(66)90246-6. [DOI] [PubMed] [Google Scholar]
  8. NILSSON I. M., OLOW B. Determination of fibrinogen and fibrinogenolytic activity. Thromb Diath Haemorrh. 1962 Nov 15;8:297–310. [PubMed] [Google Scholar]
  9. Niléhn J. E. Separation and estimation split "products" of fibrinogen and fibrin in human serum. Thromb Diath Haemorrh. 1967 Dec 31;18(3-4):487–498. [PubMed] [Google Scholar]
  10. PARASKEVAS M., NILSSON I. M., MARTINSSON G. A method for determining serum inhibitors of plasminogen activation. Scand J Clin Lab Invest. 1962;14:138–144. doi: 10.3109/00365516209079685. [DOI] [PubMed] [Google Scholar]
  11. Pandolfi M. Histochemistry and assay of plasminogen activator. Rev Eur Etud Clin Biol. 1972 Mar;17(3):254–260. [PubMed] [Google Scholar]
  12. Ruddy S., Gigli I., Austen K. F. The complement system of man. I. N Engl J Med. 1972 Sep 7;287(10):489–495. doi: 10.1056/NEJM197209072871005. [DOI] [PubMed] [Google Scholar]
  13. Thomas L. The technology of medicine. N Engl J Med. 1971 Dec 9;285(24):1366–1368. doi: 10.1056/NEJM197112092852411. [DOI] [PubMed] [Google Scholar]
  14. Zimmerman T. S., Müller-Eberhard H. J. Blood coagulation initiation by a complement-mediated pathway. J Exp Med. 1971 Dec 1;134(6):1601–1607. doi: 10.1084/jem.134.6.1601. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES